vs
BRADY CORP（BRC）与Ultragenyx Pharmaceutical Inc.（RARE）财务数据对比。点击上方公司名可切换其他公司
BRADY CORP的季度营收约是Ultragenyx Pharmaceutical Inc.的2.0倍（$405.3M vs $207.3M），BRADY CORP净利率更高（13.3% vs -62.0%，领先75.3%），Ultragenyx Pharmaceutical Inc.同比增速更快（25.9% vs 7.5%），BRADY CORP自由现金流更多（$22.4M vs $-100.8M），过去两年Ultragenyx Pharmaceutical Inc.的营收复合增速更高（38.0% vs 12.1%）
布雷迪公司是美国特种产品、技术设备及标识解决方案供应商，1914年创立，总部位于威斯康星州密尔沃基，在美洲、欧洲、亚洲、澳洲拥有6600名员工，业务覆盖全球，为各行业客户提供工作场景所需的零部件标识相关产品与服务。
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
BRC vs RARE — 直观对比
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $405.3M | $207.3M |
| 净利润 | $53.9M | $-128.6M |
| 毛利率 | 51.5% | — |
| 营业利润率 | 16.8% | -54.7% |
| 净利率 | 13.3% | -62.0% |
| 营收同比 | 7.5% | 25.9% |
| 净利润同比 | 15.3% | 3.5% |
| 每股收益（稀释后） | — | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $405.3M | $207.3M | ||
| Q3 25 | $397.3M | $159.9M | ||
| Q2 25 | $382.6M | $166.5M | ||
| Q1 25 | $356.7M | $139.3M | ||
| Q4 24 | $377.1M | $164.6M | ||
| Q3 24 | $343.4M | $139.5M | ||
| Q2 24 | $343.4M | $147.0M | ||
| Q1 24 | $322.6M | $108.8M |
| Q4 25 | $53.9M | $-128.6M | ||
| Q3 25 | $49.9M | $-180.4M | ||
| Q2 25 | $52.3M | $-115.0M | ||
| Q1 25 | $40.3M | $-151.1M | ||
| Q4 24 | $46.8M | $-133.2M | ||
| Q3 24 | $55.5M | $-133.5M | ||
| Q2 24 | $50.9M | $-131.6M | ||
| Q1 24 | $43.6M | $-170.7M |
| Q4 25 | 51.5% | — | ||
| Q3 25 | 50.4% | — | ||
| Q2 25 | 51.0% | — | ||
| Q1 25 | 49.3% | — | ||
| Q4 24 | 50.3% | — | ||
| Q3 24 | 51.6% | — | ||
| Q2 24 | 51.6% | — | ||
| Q1 24 | 50.2% | — |
| Q4 25 | 16.8% | -54.7% | ||
| Q3 25 | 14.9% | -106.9% | ||
| Q2 25 | 17.6% | -64.8% | ||
| Q1 25 | 14.4% | -102.6% | ||
| Q4 24 | 15.6% | -74.3% | ||
| Q3 24 | 19.3% | -94.6% | ||
| Q2 24 | 18.5% | -79.1% | ||
| Q1 24 | 16.7% | -151.9% |
| Q4 25 | 13.3% | -62.0% | ||
| Q3 25 | 12.6% | -112.8% | ||
| Q2 25 | 13.7% | -69.0% | ||
| Q1 25 | 11.3% | -108.5% | ||
| Q4 24 | 12.4% | -80.9% | ||
| Q3 24 | 16.1% | -95.7% | ||
| Q2 24 | 14.8% | -89.5% | ||
| Q1 24 | 13.5% | -156.8% |
| Q4 25 | — | $-1.28 | ||
| Q3 25 | — | $-1.81 | ||
| Q2 25 | — | $-1.17 | ||
| Q1 25 | — | $-1.57 | ||
| Q4 24 | — | $-1.34 | ||
| Q3 24 | — | $-1.40 | ||
| Q2 24 | — | $-1.52 | ||
| Q1 24 | — | $-2.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $182.7M | $421.0M |
| 总债务越低越好 | $115.9M | — |
| 股东权益账面价值 | $1.2B | $-80.0M |
| 总资产 | $1.8B | $1.5B |
| 负债/权益比越低杠杆越低 | 0.09× | — |
8季度趋势，按日历期对齐
| Q4 25 | $182.7M | $421.0M | ||
| Q3 25 | $174.3M | $202.5M | ||
| Q2 25 | $152.2M | $176.3M | ||
| Q1 25 | $138.5M | $127.1M | ||
| Q4 24 | $145.7M | $174.0M | ||
| Q3 24 | $250.1M | $150.6M | ||
| Q2 24 | $160.5M | $480.7M | ||
| Q1 24 | $143.9M | $112.3M |
| Q4 25 | $115.9M | — | ||
| Q3 25 | $99.8M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $90.9M | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $1.2B | $-80.0M | ||
| Q3 25 | $1.2B | $9.2M | ||
| Q2 25 | $1.2B | $151.3M | ||
| Q1 25 | $1.1B | $144.2M | ||
| Q4 24 | $1.1B | $255.0M | ||
| Q3 24 | $1.1B | $346.8M | ||
| Q2 24 | $1.0B | $432.4M | ||
| Q1 24 | $1.0B | $140.3M |
| Q4 25 | $1.8B | $1.5B | ||
| Q3 25 | $1.7B | $1.2B | ||
| Q2 25 | $1.7B | $1.3B | ||
| Q1 25 | $1.6B | $1.3B | ||
| Q4 24 | $1.6B | $1.5B | ||
| Q3 24 | $1.5B | $1.5B | ||
| Q2 24 | $1.4B | $1.6B | ||
| Q1 24 | $1.4B | $1.3B |
| Q4 25 | 0.09× | — | ||
| Q3 25 | 0.08× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.09× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $33.4M | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | $22.4M | $-100.8M |
| 自由现金流率自由现金流/营收 | 5.5% | -48.6% |
| 资本支出强度资本支出/营收 | 2.7% | 0.5% |
| 现金转化率经营现金流/净利润 | 0.62× | — |
| 过去12个月自由现金流最近4个季度 | $159.9M | $-472.0M |
8季度趋势，按日历期对齐
| Q4 25 | $33.4M | $-99.8M | ||
| Q3 25 | $58.3M | $-91.4M | ||
| Q2 25 | $59.9M | $-108.3M | ||
| Q1 25 | $39.6M | $-166.5M | ||
| Q4 24 | $23.4M | $-79.3M | ||
| Q3 24 | $84.0M | $-67.0M | ||
| Q2 24 | $72.7M | $-77.0M | ||
| Q1 24 | $36.1M | $-190.7M |
| Q4 25 | $22.4M | $-100.8M | ||
| Q3 25 | $49.4M | $-92.7M | ||
| Q2 25 | $55.6M | $-110.7M | ||
| Q1 25 | $32.5M | $-167.8M | ||
| Q4 24 | $16.1M | $-79.5M | ||
| Q3 24 | $73.2M | $-68.6M | ||
| Q2 24 | $64.4M | $-79.0M | ||
| Q1 24 | $-13.5M | $-193.9M |
| Q4 25 | 5.5% | -48.6% | ||
| Q3 25 | 12.4% | -58.0% | ||
| Q2 25 | 14.5% | -66.5% | ||
| Q1 25 | 9.1% | -120.5% | ||
| Q4 24 | 4.3% | -48.3% | ||
| Q3 24 | 21.3% | -49.2% | ||
| Q2 24 | 18.8% | -53.7% | ||
| Q1 24 | -4.2% | -178.2% |
| Q4 25 | 2.7% | 0.5% | ||
| Q3 25 | 2.2% | 0.8% | ||
| Q2 25 | 1.1% | 1.5% | ||
| Q1 25 | 2.0% | 1.0% | ||
| Q4 24 | 1.9% | 0.1% | ||
| Q3 24 | 3.1% | 1.2% | ||
| Q2 24 | 2.4% | 1.4% | ||
| Q1 24 | 15.4% | 3.0% |
| Q4 25 | 0.62× | — | ||
| Q3 25 | 1.17× | — | ||
| Q2 25 | 1.15× | — | ||
| Q1 25 | 0.98× | — | ||
| Q4 24 | 0.50× | — | ||
| Q3 24 | 1.51× | — | ||
| Q2 24 | 1.43× | — | ||
| Q1 24 | 0.83× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BRC
| Americas Asia | $215.1M | 53% |
| Europe Australia | $119.9M | 30% |
| Other | $70.2M | 17% |
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
